Oropharyngeal Cancers Recruiting Phase 2 Trials for Cetuximab (DB00002)

Also known as: Oropharyngeal Cancer / Cancer of Oropharnyx

IndicationStatusPhase
DBCOND0042409 (Oropharyngeal Cancers)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03422536Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell CarcinomaTreatment